Cymax Human IL-5 ELISA Kit
- Known as:
- Cymax Human Interleukin-5 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- lf-ek0259
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Cymax Human IL-5 ELISA Kit
Related genes to: Cymax Human IL-5 ELISA Kit
- Gene:
- CSF2RB NIH gene
- Name:
- colony stimulating factor 2 receptor beta common subunit
- Previous symbol:
- IL3RB
- Synonyms:
- IL5RB, CD131, betaGMR
- Chromosome:
- 22q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2017-07-12
- Gene:
- IL5 NIH gene
- Name:
- interleukin 5
- Previous symbol:
- -
- Synonyms:
- IL-5, EDF, TRF
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2015-07-06
- Gene:
- IL5RA NIH gene
- Name:
- interleukin 5 receptor subunit alpha
- Previous symbol:
- IL5R
- Synonyms:
- CDw125, CD125
- Chromosome:
- 3p26.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-18
- Date modifiied:
- 2016-10-11
- Gene:
- LRR1 NIH gene
- Name:
- leucine rich repeat protein 1
- Previous symbol:
- PPIL5
- Synonyms:
- MGC20689, LRR-1
- Chromosome:
- 14q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-20
- Date modifiied:
- 2014-11-18
Related products to: Cymax Human IL-5 ELISA Kit
Related articles to: Cymax Human IL-5 ELISA Kit
- Asthma is a complex, heterogeneous, and inflammatory disease with an increasing incidence worldwide. This study aimed to investigate the therapeutic mechanisms of sophocarpine in asthma systematically. - Source: PubMed
Publication date: 2026/08/24
Zhi WenbingZhang HongQiao ZiyaoJiang ShengnanLiang ZongsuoLiu Yang - Chronic eosinophilic pneumonia (CEP) is a rare, idiopathic inflammatory lung disease characterized by subacute symptoms such as cough, dyspnea, and fever; abnormal chest imaging findings; peripheral eosinophilia; and eosinophilic infiltration of the pulmonary interstitium and alveoli. Eosinophils interact with multiple T helper 2 (Th2) cellular pathways; however, eosinophil recruitment to the lung is primarily mediated by interleukin (IL)-5 and the eotaxin subfamily of chemokines. Standard treatment consists of systemic corticosteroids; however, relapse is frequent after tapering the corticosteroid dose, leading to long-term steroid therapy and its associated adverse effects, including diabetes mellitus, infections, glaucoma, and osteoporosis. - Source: PubMed
Publication date: 2026/08/14
Scelfo ChiaraSimonazzi AnnaRuggiero PatriziaPellegrino Maria RosariaFacciolongo Nicola - Aging is a major risk factor for cardiovascular diseases (CVD), partly due to the accumulation of senescent cells. Senescence is characterized by irreversible cell cycle arrest and the acquisition of a senescence associated secretory phenotype (SASP), which promotes inflammation and tissue remodeling, thereby contributing to cardiac dysfunction. Cardiac fibroblasts (CFs), key regulators of cardiac repair, differentiate into myofibroblasts (CMFs) in response to pathological stimuli such as mechanical stiffness and TGF-β1. CMFs secrete abundant extracellular matrix (ECM) proteins, and while their senescence may transiently restrict fibrosis in acute cardiac injury, persistent senescence promotes chronic remodeling through SASP activity. Given that TGF-β1 is a central mediator of CF-to-CMF differentiation and can induce senescence in various cell lines, we investigated whether it simultaneously triggers both processes in neonatal rat CFs, and whether the senotherapeutics Navitoclax and Dasatinib + Quercetin modulate the viability of senescent CMFs. - Source: PubMed
Publication date: 2026/08/14
Espinoza-Perez ClaudioOsorio José MiguelVélez RubénOrtega Bustos JuanMachuca VíctorRivas SebastiánSánchez-Ferrer Carlos FPeiró ConcepciónVivar RaúlDíaz-Araya Guillermo - Moyamoya disease (MMD) is an idiopathic cerebrovascular disorder in which chronic inflammation has been implicated, along with genetic susceptibility, including the RNF213 variants. In this study, we examined the relationship between type 2 inflammation and MMD. - Source: PubMed
Publication date: 2026/08/25
Park SilsuMineharu YoheiFunaki TakeshiChihara HideoSasagasako TomokiKamata TakahikoNakajima KotaMiyamoto SusumuArakawa Yoshiki - Eligibility for biologic therapy in severe asthma varies internationally because government-funded schemes apply stricter criteria than pivotal trials. While relaxing eligibility thresholds may expand access, the effects on prevalence and healthcare costs remain uncertain. - Source: PubMed
Publication date: 2026/08/19
Yang FredaGeisler Benjamin Pd'Ancona GrainneLee BoheeJackson David JBloom Chloe I